Equities research analysts expect Intrexon Corporation (NYSE:XON) to announce earnings per share of ($0.22) for the current quarter, according to Zacks. Four analysts have made estimates for Intrexon Corporation’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.30). Intrexon Corporation reported earnings per share of ($0.24) during the same quarter last year, which would suggest a positive year over year growth rate of 8.3%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Intrexon Corporation will report full-year earnings of ($0.84) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.55). For the next year, analysts expect that the firm will post earnings of ($0.66) per share, with EPS estimates ranging from ($0.75) to ($0.57). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Intrexon Corporation.

Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.42) earnings per share.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Northland Securities reissued a “buy” rating and issued a $27.00 price target on shares of Intrexon Corporation in a research report on Friday, October 6th. Griffin Securities reissued a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research report on Friday, October 6th. JMP Securities reissued an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, BidaskClub cut shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $43.20.

In other Intrexon Corporation news, COO Andrew J. Last acquired 2,000 shares of the company’s stock in a transaction on Monday, August 14th. The shares were bought at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the completion of the purchase, the chief operating officer now owns 2,000 shares in the company, valued at approximately $39,980. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dean J. Mitchell acquired 5,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $18.33 per share, for a total transaction of $91,650.00. Following the completion of the purchase, the director now owns 18,103 shares of the company’s stock, valued at approximately $331,827.99. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 144,569 shares of company stock worth $2,719,429. 55.10% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in Intrexon Corporation by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares during the period. Federated Investors Inc. PA acquired a new position in Intrexon Corporation in the second quarter valued at $172,000. SG Americas Securities LLC acquired a new position in Intrexon Corporation in the first quarter valued at $164,000. Cullinan Associates Inc. acquired a new position in Intrexon Corporation in the second quarter valued at $201,000. Finally, Principal Financial Group Inc. acquired a new position in Intrexon Corporation in the second quarter valued at $212,000. Institutional investors own 82.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/0-22-eps-expected-for-intrexon-corporation-xon-this-quarter.html.

Intrexon Corporation (NYSE:XON) opened at 17.88 on Monday. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90. The firm’s market capitalization is $2.15 billion. The stock’s 50 day moving average price is $19.05 and its 200-day moving average price is $20.99.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon Corporation (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.